Astorg takes majority stake in Nemera
Context
The acquisition of Nemera by Astorg Partners is a strategic move to capitalize on the company's strong market position, predictable revenue streams, and significant growth potential. The deal is driven by the attractiveness of Nemera's business model, which is characterized by long-term contracts, high recurrence rates, and a strong track record of EBITDA growth. Astorg Partners' investment in Nemera is expected to support the company's continued growth and expansion, with a focus on driving innovation, improving operational efficiency, and enhancing customer satisfaction. The transaction is also expected to provide a strong return on investment for Astorg Partners, given Nemera's solid financial performance and growth prospects. The deal process was highly competitive, with several strategic and financial buyers participating in the auction, and Astorg Partners' offer was distinguished by its attractive financial terms and compelling growth strategy.
In the past, Nemera was acquired by Montagu Private Equity in 2014 as part of its expansion strategy.
Nemera, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Nemera
Other operations with Astorg
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2021 | ASTORG | XCEPTOR | UNITED KINGDOM | Financial Services / Banking |
| 06/2020 | ASTORG | NORMEC | NETHERLANDS | TIC (Testing, Inspection, Certification) |
| 04/2020 | CINVEN / ASTORG | LGC GROUP | UNITED KINGDOM | TIC (Testing, Inspection, Certification) |
| 02/2019 | ASTORG | ANAQUA | UNITED STATES | Industry-Specific Software |
| 04/2016 | ASTORG | FLOWBIRD (EX PARKEON) | FRANCE | Industry-Specific Software |
| 02/2016 | ASTORG / GOLDMAN SACHS | HRA PHARMA | FRANCE | Generics / Labs |
| 04/2015 | ASTORG | METROLOGIC GROUP | FRANCE | Supply Chain & Ops |
| 12/2013 | ASTORG | KERNEOS | FRANCE | Construction Materials |
| 11/2007 | ASTORG | TRESCAL | FRANCE | TIC (Testing, Inspection, Certification) |
| 04/2007 | ASTORG | ETHYPHARM | FRANCE | Pharma & Biotech |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2018 | MERCK & CO. | ANTELLIQ | FRANCE | Animal Health |
| 11/2018 | ARDIAN | NEOPHARMED GENTILI | ITALY | Generics / Labs |
| 10/2018 | ARDIAN | INULA GROUP | BELGIUM | Pharma & Biotech |
| 10/2018 | GLANBIA | SLIMFAST | UNITED STATES | Nutrition & Dietary Supplements |
| 10/2018 | BRIDGEPOINT | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 08/2018 | DENTRESSANGLE | ACTEON | FRANCE | Medical Devices |
| 05/2018 | NN | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 05/2018 | ZOETIS | ABAXIS | UNITED STATES | Diagnostic Equipment |
| 05/2018 | PERMIRA | CORIN GROUP | UNITED KINGDOM | Implants & Prosthetics |
| 12/2017 | PERKINELMER | EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS | GERMANY | Diagnostic Equipment |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €250–500M
EBITDA range: €50–100M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nemera by Astorg are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: nemera
FAQ
What transaction does this page cover?
How was the acquisition of Nemera by Astorg valued, and what multiples were paid?
What were Nemera’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?